Aurobindo Pharma Limited has informed the Exchange about Action(s) taken or orders passed by CESTAT, Chennai.
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aurobindo Pharma received an order from CESTAT Chennai on June 6, 2025, dismissing its appeal against a 2015 Customs Commissioner order. The original dispute relates to alleged non-fulfilment of export obligations under two Advance Authorizations. The total disputed amount is Customs Duty of about Rs. 29.17 lakhs, a redemption fine of Rs. 50 lakhs, and a penalty of Rs. 10 lakhs, along with applicable interest. The company argued that there was only a delay in fulfilling export obligations and that it had sought an extension from the Director General Foreign Trade. The company plans to file a further appeal in the High Court against the CESTAT order. The company has stated that there is no material impact on its financials or operations from this order.
This is a minor legal setback for Aurobindo Pharma, but the company says the financial impact is not material given the relatively small disputed amount (under Rs. 1 crore total). Shareholders are unlikely to see any meaningful effect on the stock, though the upcoming High Court appeal will be worth watching.